combination therapy

Research in Review

High Potential for Drug-Drug Interactions With New Antineoplastic Agents

11/03/2016

JCP Editors

Most oral antineoplastic drugs approved in the past six years are associated with multiple, clinically significant drug-drug interactions (DDIs). Therefore, the onus remains on oncologists to be more of aware DDIs...

Most...

11/03/2016

Journal of Clinical Pathways

Research in Review

Drug Combination Does Not Benefit Patients With Colorectal Cancer

09/26/2016

JCP Editors

There is no benefit from the addition of bevacizumab to capecitabine in the adjuvant setting for colorectal cancer, according to results from a clinical trial. Bevacizumab, along with other angiogenesis inhibitors,...

There...

09/26/2016

Journal of Clinical Pathways

Research in Review

HAPs Prevent Treatment Resistance in EGFR+ NSCLC

09/12/2016

JCP Editors

Adding a hypoxia-activated prodrug (HAP) to standard care for epidermal growth factor receptor-positive non-small cell lung cancer may help to delay treatment resistance, according to a study published in PLOS...

Adding...

09/12/2016

Journal of Clinical Pathways

Research in Review

Early Trials Show Promising Results for Lymphoma Immunotherapy Drug

12/10/2015

JCP Editors

SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial on Saturday at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida...

...

12/10/2015

Journal of Clinical Pathways

Research in Review

In Head-to-Head Study, New Multiple Myeloma Drug Combination Shows Superiority

12/07/2015

JCP Editors

A phase 3 head-to-head trial comparing the effectiveness of Kyprolis (carfilzomib) in combination with dexamethasone has shown better outcomes in patients with multiple myeloma than the current standard of care,...

A...

12/07/2015

Journal of Clinical Pathways

Research in Review

Novel Lung Cancer Vaccine Beneficial, but Only for Certain Patients

11/06/2015

JCP Editors

A study of a new novel vaccine for the treatment of non-small cell lung cancer (NSCLC) may have found potential benefits for specific patients who initiate immunotherapy within 12 weeks of completing chemotherapy and...

A...

11/06/2015

Journal of Clinical Pathways